Njbio India Pharmaceutical Private Limited - Company Profile

It is a travel and hospitality private limited company based in Mumbai, Maharashtra, India, established in 2019.
2019 Mumbai, Maharashtra, India Active
Last Updated:
Access Report
About Njbio India Pharmaceutical Private Limited

Njbio India Pharmaceutical Private Limited, a active private limited company, was established on 10 January 2019 in Mumbai, Maharashtra, India. Engaging in consumer professional services within the professional, scientific and technical sector, it holds CIN: U73100MH2019PTC319319. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹20.00 Cr and a paid-up capital of ₹16.37 Cr.

Formerly known as Amar Chemistry Private Limited. It upholds a compliant status. Employing 38 professional, Its leadership includes Arpit Pokharna (Director), Rahul Suresh Bagul (Whole-Time Director), Nareshkumar Fulchand Jain (Director). Past directors included Arpit Pokharna, Arpit Pokharna, Vishal Naresh Shah. It holds no open charges and ₹8.16 Cr settled loans. Its latest AGM occurred on 22 August 2025, with the balance sheet filed on 31 March 2025. It is based at G-1, G-1A, Ground Floor, Ackruti Corporate Park, Cts No 586,586/1,Lbs Marg,Kanjur Village, ,Bhandup W, Mumbai, Maharashtra, 400078.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U73100MH2019PTC319319

  • Registration Number

    319319

  • Incorporation Date

    10 January 2019

  • Authorized Capital

    ₹20.00 Cr

  • Paid-Up Capital

    ₹16.37 Cr

  • ROC Code

    Roc Mumbai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 20.00 Cr
  • Paid Up Capital ₹ 16.37 Cr
  • Company Age 7 Year, 4 Months
  • Last Filing with ROC 31 Mar 2025
  • Satisfied Charges ₹ 8.16 Cr
  • Revenue Growth **** 114.92%
  • Profit Growth **** 235.45%
  • Ebitda **** 3113.67%
  • Net Worth 258.45%
  • Total Assets **** 8.21%
Company report

Njbio India Pharmaceutical Private Limited

Company Report FY 2026-2027

Comprehensive Company Insights

Explore comprehensive insights into Njbio India Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Njbio India Pharmaceutical Private Limited?
Current Directors
Name Designation Appointment Date Status
Arpit Pokharna Director 01 Sep 2023 Current
Rahul Suresh Bagul Whole-Time Director 16 Dec 2024 Current
Nareshkumar Fulchand Jain Director 10 Jan 2019 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 28 Sep 2023 Past
Pramod Abcsdd Cfo - Past
Pramod Abcsdd Managing Director 01 Sep 2023 Past
Pramod Abcsdd Additional Director 30 Sep 2019 Past
Pramod Abcsdd Additional Director 23 Apr 2025 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Njbio India Pharmaceutical.

Njbio India Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 114.92% increase. The company also saw a substantial improvement in profitability, with a 235.45% increase in profit. The company's net worth Soared by an impressive increase of 258.45%.

Njbio India Pharmaceutical revenue growth over time
Njbio India Pharmaceutical profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 114.92%
*******
*******
*******
*******
Revenue from Operations
*******
 115.94%
*******
*******
*******
*******
Total Assets
*******
 8.21%
*******
*******
*******
*******
Profit or Loss
*******
 235.45%
*******
*******
*******
*******
Net Worth
*******
 258.45%
*******
*******
*******
*******
EBITDA
*******
 3113.67%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Njbio India Pharmaceutical?

In 2023, Njbio India Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹0

Satisfied Charges

₹81,615,600.00

Charges Breakdown by Lending Institutions
  • Hdfc Bank Limited : 8.16 Cr
Latest Charge Details
Date Lender Amount Status
20 Aug 2019 Hdfc Bank Limited ₹8.16 Cr Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Njbio India Pharmaceutical?

Njbio India Pharmaceutical has a workforce of 38 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Njbio India Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Njbio India Pharmaceutical's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Njbio India Pharmaceutical
Recent Activity within the Organization
  • Director Appointment

    The activity Tanveer Fatima was appointed as a Company Secretary was appointed as a Company Secretary on 12 Sep 2025 & has been associated with this company since 8 months 8 days . was completed.

  • Annual General Meeting

    The activity Njbio India Pharmaceutical Private Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records. was completed.

  • Director Appointment

    Swati Mathur was appointed as a Cfo was appointed as a Cfo on 03 Jul 2025 & has been associated with this company since 10 months 18 days . was recorded as a recent event.

  • Balance Sheet

    The activity Njbio India Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.

  • Director Appointment

    Progress on Rahul Suresh Bagul was appointed as a Whole-time director was appointed as a Whole-time director on 16 Dec 2024 & has been associated with this company since 1 year 5 months . was documented.

  • Director Appointment

    Arpit Pokharna was appointed as a Director was appointed as a Director on 01 Sep 2023 & has been associated with this company since 2 years 8 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Njbio India Pharmaceutical Private Limited?

The CIN of Njbio India Pharmaceutical Private Limited is U73100MH2019PTC319319.

Where is Njbio India Pharmaceutical Private Limited headquartered?

Njbio India Pharmaceutical Private Limited is headquartered at G-1, G-1A, Ground Floor, Ackruti Corporate Park, Cts No 586,586/1,Lbs Marg,Kanjur Village, ,Bhandup W, Mumbai, Maharashtra, 400078.

When was Njbio India Pharmaceutical Private Limited incorporated?

Njbio India Pharmaceutical Private Limited was incorporated on 10 January 2019.

Who are the current directors of Njbio India Pharmaceutical Private Limited?

The current directors of Njbio India Pharmaceutical Private Limited are

What is the primary industry of Njbio India Pharmaceutical Private Limited?

The primary industry of Njbio India Pharmaceutical Private Limited is Professional, Scientific And Technical.

Is Njbio India Pharmaceutical Private Limited a listed company?

Njbio India Pharmaceutical Private Limited is unlisted.

What is the capital structure of Njbio India Pharmaceutical Private Limited?

The authorized capital of Njbio India Pharmaceutical Private Limited is ₹20.00 Cr, and the paid-up capital is ₹16.37 Cr.

What is the compliance status of Njbio India Pharmaceutical Private Limited?

The compliance status of Njbio India Pharmaceutical Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available